A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

10.8K views

⸱

DOI:

10.3791/52752

⸱

May 30th, 2015

 ,  ,  ,  ,  ,  ,  ,  , 

In This Article

Summary

An ELISA offering a novel quantitative approach is described. It specifically detects disease-associated α-synuclein (αSD) in a transgenic mouse model (M83) of synucleinopathy using several antibodies against either the Ser129 phosphorylated αS form or the C-terminal part of the protein.

Abstract

In addition to established methods like Western blot, new methods are needed to quickly and easily quantify disease-associated α-synuclein (αSD) in experimental models of synucleopathies. A transgenic mouse line (M83) over-expressing the human A53T αS and spontaneously developing a dramatic clinical phenotype between eight and 22 months of age, characterized by symptoms including weight loss, prostration, and severe motor impairment, was used in this study. For molecular analyses of αSD (disease-associated αS) in these mice, an ELISA was designed to specifically quantify αSD in sick mice. Analysis of the central nervous system in this mouse model showed the presence of αSD mainly in the caudal brain regions and the spinal cord. There were no differences in αSD distribution between different experimental conditions leading to clinical disease, i.e., in uninoculated and normally aging transgenic mice and in mice inoculated with brain extracts from sick mice. The specific detection of αSD immunoreactivity using an antibody against Ser129 phosphorylated αS by ELISA essentially correlated with that obtained by Western blot and immunohistochemistry. Unexpectedly, similar results were observed with several other antibodies against the C-terminal part of αS. The propagation of αSD, suggesting the involvement of a “prion-like” mechanism, can thus be easily monitored and quantified in this mouse model using an ELISA approach.

Introduction

Most current methods for detecting disease-associated α-synuclein (αSD) in experimental models of Parkinson's disease (PD), such as immunohistochemistry or Western blot, are time-consuming and not quantitative. This neurodegenerative disease is characterized by alpha-synuclein aggregation mainly in the form of inclusions containing an aggregated form of the normally soluble presynaptic protein αS1,2 (Lewy bodies and Lewy neurites). Normally only marginally phosphorylated, αS is hyperphosphorylated at its serine 129 residue in these inclusions3 and can be monitored by antibodies specifically directed against Ser129 p....

Access restricted. Please log in or start a trial to view this content.

Protocol

All the procedures and protocols involving animals were in accordance with EC Directive 86/609/EEC and ratified by ComEth, the French national committee for consideration of ethics in animal experimentation (protocol 11-0043). The animals were housed and cared for in ANSES’s approved experimental facilities in Lyon (approval B 69387 0801).

1. Preparation of Mice

  1. Euthanize mice by an intraperitoneal injection of lethal dose of sodium pentobarbital.
  2. Retrieve the whole brain from the mouse skull and place it in a 35 mm plastic Petri dish on ice until extraction.
  3. Extract the cervical spinal cord.

Access restricted. Please log in or start a trial to view this content.

Results

In this study, the ELISAs used specifically identified disease-associated αS (αSD) in brain homogenates prepared in a High Salt buffer from sick M83 mice. Using an antibody specifically recognizing pSer129 αS (p = 0.0074), the ELISA readily distinguishes old, sick mice (> 8 months old) from young (2-5 months old), healthy M83 mice (Figure 1). Several other antibodies showed similarly high signals (> 0.6 OD) only in brain homogenates from sick mice. This is the case for 4D6 (p = 0.01), LB.......

Access restricted. Please log in or start a trial to view this content.

Discussion

The use of an ELISA was demonstrated to specifically detect αSD directly from mouse brain homogenates during the disease in the M83 transgenic mouse model. Indeed, this ELISA could readily distinguish sick M83 mice from healthy M83 mice using only whole brain homogenates in High Salt buffer.

The most critical steps for successful results using this ELISA are: correctly dissecting the different regions of the mouse brains by developing the necessary manual dexterity to prevent d.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have no competing interests to disclose.

Acknowledgements

The authors would like to thank Damien Gaillard for inoculations and follow-up of animal experiments. This work was supported by ANSES (French Agency for Food, Environmental and Occupational Health & Safety) and by a grant from the Foundation France Parkinson.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
LB509Abcamab27766Detection antibody 1/2,000
AS11Produced at AnsesDetection antibody 1/1,000
4D6Abcamab1903Detection antibody 1/2,000
PSer129Abcamab59264Detection antibody 1/3,000
PSer129 EP1536YAbcamab51253Detection antibody 1/1,000
syn514Abcamab24717Detection antibody 1/500
clone 42BD Biosciences610787Coating and detection antibody (1/2,000)
8A5Provided by Dr. AndersonDetection antibody 1/2,000
polyclonal anti-αsyn antibodyMilliporeAB5038PCoating antibody
Anti-mouse IgG HRP conjugateSouthern Biotech1010-05
Anti-rabbit IgG HRP conjugateSouthern Biotech4010-05
Goat anti-mouse IgG HRP conjugateDianova115-035-164
HS bufferAdjust at pH 7.5 and keep at 4 °C
  • Tris-HCl 50 mM
Euromedex26-128-3094-B
  • NaCl 750 mM
Euromedex1112-A
  • EDTA 5 mM
EuromedexEU0007-B
  • DTT 1 mM
Sigma43815
PBSAdjust at pH 7.5
  • Na2HPO4 1 mM
Euromedex1309
  • KH2PO4 1.5 mM
Euromedex2018
  • NaCl  137 mM
Euromedex1112-A
  • KCl 2.7 mM
EuromedexP017
Tween 20Euromedex2001-C
BSASigmaA7906
DTT 1 mMSigma43815Stock solution 100 mM, toxic
1% phosphatase cocktailPierce78428
1% protease inhibitor cocktailRoche04 693 132 00150x concentrated
Microplate MaxiSorpTMThermo Scientific442404
Tampon carbonate 50 mM pH 9.6
  • Na2CO3, 10H2O
Sigma713602.86 g/L
  • NaHCO3
Merk63293.36 g/L, pH 9.6
Superblock T20 PBS blocking bufferPierceE6423H10x concentrated
TMBSigmaT0440Used for ELISA
TMBAnalytik Jena AG847-0104200302Used for epitope mapping
HCl 1 NChimie plus40030
RibolyserThermoFast prep FP120keep on ice at this step
Grinding tubesBiorad355-1197
Plate washerTecanColumbus Pro
Plate readerBioradModel 680
Low power magnifier VWR630-10628X magnification
Forceps Dumont#7WPI14097For dissection steps
Transfer pipette 1ml SamsoSamso043231
1.5 ml tubesDutscher033290

References

  1. Goedert, M., Spillantini, M. G., Del Tredici, K., Braak, H. 100 years of Lewy pathology. Nat Rev Neurol. 9, 13-24 (2013).
  2. Waxman, E. A., Giasson, B. I. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol. 6....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Alpha Synuclein DetectionELISA MethodDisease-associated Alpha SynucleinBrain Homogenate PreparationWestern Blot ComparisonPhospho-Ser129 AntibodySpinal Cord AnalysisMesencephalon BrainstemPrion-like Propagation